Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBT Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBT Margin for 6 consecutive years, with 162.11% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 4226.0% to 162.11% in Q3 2025 year-over-year; TTM through Sep 2025 was 846.98%, a 80629.0% increase, with the full-year FY2024 number at 5340.68%, down 491659.0% from a year prior.
  • EBT Margin was 162.11% for Q3 2025 at Marker Therapeutics, up from 479.92% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 91.5% in Q4 2024 to a low of 3609.7% in Q4 2023.
  • A 4-year average of 661.78% and a median of 385.86% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -322383bps in 2023, then surged 370120bps in 2024.
  • Marker Therapeutics' EBT Margin stood at 385.86% in 2022, then plummeted by -835bps to 3609.7% in 2023, then skyrocketed by 103bps to 91.5% in 2024, then plummeted by -277bps to 162.11% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's EBT Margin are 162.11% (Q3 2025), 479.92% (Q2 2025), and 1273.6% (Q1 2025).